Choosing between pharma digital marketing companies is not really a creative pitch exercise. It is a risk decision. The right partner can grow qualified demand while protecting the brand from claims problems, audience leakage, weak consent handling, and reporting nobody can use. The wrong partner can produce polished assets that legal, medical, regulatory, and procurement teams then spend months unpicking.
Use this guide to shortlist agencies for UK pharmaceutical, OTC, medical device, clinic, life sciences, and regulated healthcare work. If you need a partner for regulated healthcare growth, start with Teapot’s pharma marketing work or book a focused conversation through contact.
| Decision area | What good looks like | Red flag |
|---|---|---|
| Compliance | Clear claims review, audience separation, adverse event routing | ”Legal will check it later” |
| SEO and content | Evidence-led pages mapped to patient, HCP, and purchaser intent | Generic blog calendar |
| Paid media | Channel rules checked before creative production | Same ads as consumer e-commerce |
| Analytics | Consent-aware reporting tied to qualified actions | Traffic, impressions, and no lead quality |
What should a regulated healthcare partner actually do?
A regulated healthcare partner should turn commercial goals into campaigns that can survive medical review, platform review, and public scrutiny. Strategy, content, SEO, paid media, UX, analytics, and governance cannot sit in separate lanes. They need to work as one system.
In UK pharma, the partner also needs to understand the line between information, disease awareness, and promotion. The MHRA’s Blue Guide for advertising and promotion of medicines was updated on 28 March 2025, and MHRA’s Advertise your medicines guidance was last updated on 11 April 2025. Do not hire a digital partner that treats regulated claims as a final proofreading step.
For prescription-only medicines, public promotion is especially sensitive. If an agency cannot explain how it separates HCP journeys from public journeys across a website, landing page, LinkedIn campaign, paid search account, and analytics dashboard, it is not ready for regulated work.
A capable partner should ask early: is this OTC, POM, device, service, or disease awareness? Is the audience the public, HCPs, pharmacists, payers, private clinics, distributors, or procurement? Which claims are already approved? Who owns pharmacovigilance routing if a comment or form submission contains a reportable signal?
How do you screen for compliance competence?
Screen for compliance competence by asking for the workflow, not the promise. A serious partner can show how a claim moves from source evidence into copy, creative, review, publication, and post-launch monitoring.
Use a 30-minute compliance screen before any creative presentation:
| Question | Strong answer | Weak answer |
|---|---|---|
| How do you manage claims? | Claim matrix with source, audience, approval status, expiry, and allowed wording | Copywriter notes in a document |
| How do you handle HCP-only material? | Gated or clearly separated journeys with audience intent documented | Same page with a small disclaimer |
| How do you route adverse events? | Written escalation path, named owner, and response time | ”The community manager will flag it” |
| How do you brief paid media? | Platform policy review before creative, targeting, and landing page build | Upload first, appeal later |
| How do you store approvals? | Versioned audit trail by asset and channel | Email thread archaeology |
Regulated marketing fails when the workflow is informal. A single unapproved superlative, unsupported visual implication, or HCP message visible to the public can create rework and reputational risk. Ask for a past example where compliance changed the strategy. “Legal approved it” is not proof that the agency understands the risk.
What proof should be in the proposal?
The proposal should prove category judgement, not just capability. Ask for a claim matrix, regulated SEO structure, paid media risk plan, dashboard mock-up, and review calendar.
Budget claims need caution. UK regulated healthcare retainers vary by scope, seniority, medical writing input, language count, and review burden. The lowest quote is often low because claim handling, landing page QA, consent-mode analytics, or monitoring has quietly been moved back to your internal team.
Do not over-score awards, office size, or pitch polish. In regulated healthcare, the dull artefacts matter more: approval logs, evidence tables, QA checklists, redirect maps, consent notes, and records of rejected claims.
How should SEO and content work in regulated healthcare?
SEO and content should start with intent separation. A patient, caregiver, HCP, pharmacist, distributor, and NHS decision maker may search similar words, but they need different pages, evidence, language, and calls to action.
For pharma SEO, the agency should map topics into at least four content types:
| Content type | Best use | Approval risk |
|---|---|---|
| Disease awareness | Public education, symptom literacy, category demand | High if it drifts into product implication |
| HCP education | Clinical detail, mode of action, evidence summaries | High if access and audience are unclear |
| OTC product support | Public product pages, usage, contraindication signposting | Medium to high depending on claims |
| Corporate authority | Manufacturing, distribution, ESG, careers, partnerships | Lower, but still needs factual accuracy |
The content plan should be a search architecture, not “four articles per month”. Which topics deserve evergreen pages? Which should be gated? Which belong on product pages? Which need medical reviewer input? Which should be avoided because the query sits too close to prohibited public promotion?
Teapot’s practical rule: every regulated healthcare content brief needs a “claim risk line” covering audience, allowed claim territory, proof source, forbidden angle, and desired conversion. If the brief cannot define those five things, writing has started too early. The agency should also handle crawl diagnostics, schema recommendations, redirect handling, Core Web Vitals, and content pruning, not stop at keyword research.
How should paid media be evaluated?
Paid media should be evaluated by allowed message, audience control, landing page suitability, and measurement quality. A regulated paid campaign that gets clicks but keeps triggering platform disapprovals is not efficient.
For UK healthcare campaigns, the channel plan should list the practical constraint for each channel before any creative is produced:
| Channel | Useful for | Main constraint |
|---|---|---|
| Google Search | Capturing active demand for category, condition, clinic, or product-support queries | Policy review, landing page wording, and medical claim sensitivity |
| HCP, payer, distributor, employer brand, and B2B life sciences targeting | Public visibility of posts and comment moderation | |
| Programmatic | Awareness among defined professional or contextual audiences | Inventory quality and weak post-click intent |
| Meta | Consumer health awareness and OTC-adjacent education where permitted | Sensitive health targeting and claim restrictions |
| HCP nurturing and customer education with consent | List provenance, unsubscribe handling, and approval versioning |
Ask for a “blocked message list” as well as an ad plan. The blocked list proves the agency knows where not to push. Paid media reporting should also include rejected ads, approval delays, comment moderation notes, and landing page changes. Those are operational data, not embarrassing extras.
What analytics setup is credible?
A credible analytics setup connects consent, channel, content, and lead quality. In healthcare, “more traffic” is too weak because public curiosity, HCP engagement, and commercial demand can look similar once they are flattened into an aggregate dashboard.
Minimum reporting should include:
- Qualified actions by audience type, not only total conversions.
- Landing page performance by claim territory or content type.
- Organic visibility for approved topic clusters.
- Paid media spend by approved, rejected, and revised creative.
- Form quality notes from sales, medical information, or customer service.
- Consent-mode impact on observable data.
The agency should explain what it cannot measure. Consent settings, cookie rules, CRM quality, call tracking, and internal lead triage can all affect attribution. The useful dashboard is usually a weekly operating view: what was published, approved, blocked, improved, rejected, or qualified.
Teapot’s decision framework: the 5-gate shortlist
Use this 5-gate framework before inviting pharma digital marketing companies to a final pitch. It saves time because agencies that fail gate 1 or 2 rarely recover later.
| Gate | Pass condition | Reject condition |
|---|---|---|
| 1. Regulated fit | They can explain UK public vs HCP audience separation without prompting | They speak only about brand awareness and creative |
| 2. Proof system | They use claim matrices, evidence logs, and approval trails | They rely on client legal review as the control |
| 3. Channel realism | They say where SEO, content, PPC, social, and email should not be used | Every channel is recommended |
| 4. Commercial clarity | They define qualified actions and lead quality before campaign KPIs | They promise traffic or reach without business context |
| 5. Operating rhythm | They show review timelines, QA steps, and reporting cadence | The process begins with content production |
Score each gate 0, 1, or 2. A serious shortlist candidate should score at least 8 out of 10 before chemistry meetings. If two agencies score similarly, choose the one that identifies more constraints. A sensible first engagement is often a small diagnostic: one topic cluster, one claims review model, one analytics view, and one paid media constraint map.
Not For You
This approach is not for teams that want a fast campaign without internal review capacity. If your medical, legal, regulatory, product, or commercial owners cannot review material on time, even a good agency will move slowly.
It is also not for brands that want the agency to “find a way around” platform or medicines rules. The right partner will sometimes stop a campaign, remove a strong-sounding claim, or recommend a less aggressive landing page. That can feel frustrating when sales targets are high, but it is better than building demand on material that should not have gone live.
One line a weak supplier will not say: if your strongest sales claim cannot be substantiated for the intended audience, your digital problem is not media buying. It is evidence, positioning, or approval readiness.
Questions to ask before signing
Before signing, ask questions that expose operating reality:
- Which UK healthcare codes or guidance shape this project?
- Which claims would you refuse without stronger evidence?
- How do you separate public, patient, HCP, and commercial buyer journeys?
- How do you handle social comments that may include adverse events?
- Which paid platforms are risky for our use case, and why?
- What will the first 30 days produce besides meetings?
- How will you prove lead quality, not only traffic?
The best answers are specific and inconvenient. Easy answers usually miss the real constraints.
FAQ
Are pharma specialists always better than general digital agencies?
Not always. A pharma specialist can still be weak at SEO, analytics, or conversion design. A general agency can be useful if it has documented regulated healthcare workflows and senior medical-review discipline. For most UK pharma and healthcare teams, the best fit is a hybrid: regulated category judgement plus strong digital execution.
How many agencies should be invited to pitch?
Three is often enough once the compliance screen is complete. Larger pitch lists can reward theatre and make the operating model harder to inspect.
Should the agency own medical approval?
No. The agency can prepare evidence, organise claims, challenge wording, and maintain approval trails, but final approval should sit with the client’s appropriate medical, legal, regulatory, or responsible signatory process. The agency’s role is to make approval easier and safer, not to replace governance.
What is the biggest red flag in a healthcare marketing proposal?
The biggest red flag is a proposal that recommends channels before defining audience, claim territory, evidence, and measurement. In regulated healthcare, channel-first planning creates avoidable risk because the same message may be acceptable in one audience context and unacceptable in another.
